SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Goodnough, L. T. Articles by Brugnara, C. Search for Related Content PubMed PubMed Citation Articles by Goodnough, L. T. Articles by Brugnara, C. Related Collections Hematopoiesis and Stem Cells Red Cells Review Articles Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 96 No. 3 (August 1), 2000: pp. 823-833 REVIEW ARTICLE Erythropoietin, iron, and erythropoiesis Lawrence T. Goodnough, Barry Skikne, and Carlo Brugnara From the Departments of Medicine and Pathology and Immunology, Washington University School of Medicine, St. Louis, MO; the Department of Medicine, University of Kansas Medical Center, Kansas City, KS; and the Departments of Laboratory Medicine and Pathology, Children's Hospital, Harvard Medical School, Boston, MA.     Abstract Top Abstract Introduction Blood loss anemia through... Iron-restricted erythropoiesis... Anemia of chronic renal... Laboratory evaluation Clinical management: iron... Conclusion References Recent knowledge gained regarding the relationship between erythropoietin, iron, and erythropoiesis in patients with blood loss anemia, with or without recombinant human erythropoietin therapy, has implications for patient management. Under conditions of significant blood loss, erythropoietin therapy, or both, iron-restricted erythropoiesis is evident, even in the presence of storage iron and iron oral supplementation. Intravenous iron therapy in renal dialysis patients undergoing erythropoietin therapy can produce hematologic responses with serum ferritin levels up to 400 µg/L, indicating that traditional biochemical markers of storage iron in patients with anemia caused by chronic disease are unhelpful in the assessment of iron status. Newer measurements of erythrocyte and reticulocyte indices using automated counters show promise in the evaluation of iron-restricted erythropoiesis. Assays for serum erythropoietin and the transferrin receptor are valuable tools for clinical research, but their roles in routine clinical practice remain undefined. The availability of safer intravenous iron preparations allows for carefully controlled studies of their value in patients undergoing erythropoietin therapy or experiencing blood loss, or both. (Blood. 2000;96:823-833) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Blood loss anemia through... Iron-restricted erythropoiesis... Anemia of chronic renal... Laboratory evaluation Clinical management: iron... Conclusion References Several clinical settings have served as "natural experiments" that have furthered our understanding of the relationship between erythropoietin, iron, and the erythropoietic response to anemia in humans. In a review nearly 20 years ago, Finch1 summarized the knowledge gained primarily from studies of healthy persons, patients with hereditary hemolytic anemias, and patients with hemochromatosis. Under conditions of basal erythropoiesis in normal subjects, plasma iron turnover (as an index of marrow erythropoietic response) is little affected, whether transferrin saturation ranges from very low to very high levels. In contrast, the erythropoietic response in patients with congenital hemolytic anemia, in whom erythropoiesis is chronically raised as much as 6 times over basal levels,2 is affected (and limited) by serum iron levels and by transferrin saturation.3 Patients with hemochromatosis who underwent serial phlebotomy were observed to mount erythropoietic responses as much as 8 times over basal rates, attributed to the maintenance of very high serum iron and transferrin saturation levels in these patients,4 whereas healthy persons have been shown to have difficulty providing sufficient iron to support rates of erythropoiesis more than 3 times basal rates.5 These observations led Finch6 to identify a "relative iron deficiency" state that occurs when increased erythron iron requirements exceed the available supply of iron, even in the presence of storage iron. The recent practice of multiple phlebotomies through autologous blood donation in patients who are scheduled for elective surgery is also a natural experiment in blood loss anemia. This review summarizes insight gained in the past 20 years regarding the relationship between erythropoietin, iron, and erythropoiesis in patients with anemia, along with implications for patient management.     Blood loss anemia through autologous phlebotomy Top Abstract Introduction Blood loss anemia through... Iron-restricted erythropoiesis... Anemia of chronic renal... Laboratory evaluation Clinical management: iron... Conclusion References Erythropoiesis mediated by endogenous erythropoietin Patients undergoing autologous blood phlebotomy may donate 10.5 mL/kg (450 ± 45 mL) blood as often as twice a week until 72 hours before surgery.7 Under routine conditions, patients usually donate once a week.8 Oral iron supplements are routinely prescribed. This iatrogenic blood loss is accompanied by a response in endogenous erythropoietin levels that, though increased significantly over basal levels, remain within the range of normal (4-26 µm/mL).9 The erythropoietic response that occurs under these conditions is modest.8,10 A summary of selected prospective, controlled trials11-16 of patients undergoing phlebotomy is presented in Table 1. Calculated estimates of red blood cell (RBC) volume expansion (erythropoiesis in excess of basal rates) were determined17; 220 to 351 mL (11% to 19% RBC expansion,11,12 or the equivalent to 1 to 1.75 U blood18) are produced in excess of basal erythropoiesis, defining the efficacy of this blood conservation practice.                                View this table: [in this window] [in a new window]   Table 1. Endogenous erythropoietin-mediated erythropoiesis For patients subjected to more aggressive (up to 2 U a week) phlebotomy, the endogenous erythropoietin response is more substantial.13-16 In one clinical trial,14 a linear-logarithmic relationship was demonstrated between change in hemoglobin level and erythropoietin response,19 predicted previously by phlebotomy experiments in normal subjects.20 Erythropoietin-mediated erythropoiesis in this setting is 397 to 568 mL (19% to 26% RBC expansion,13-16 or the equivalent of 2 to 3 U blood18). Erythropoiesis mediated by erythropoietin therapy Clinical trials have demonstrated a dose-response relationship between erythropoietin and red blood cell expansion.16 A study of "very low" dose erythropoietin therapy in autologous blood donors found that 400 U/kg administered over a 2-week interval resulted in clinically significant erythropoiesis.21 Table 2 details red cell volume expansion in 134 patients treated with erythropoietin therapy during aggressive blood phlebotomy,14-16,22,23 ranging from 358 to 1764 mL (28% to 79% RBC expansion) over 25 to 35 days, or the equivalent of 2 to 9 U blood.18 The range in response (erythropoiesis) to dose (erythropoietin) is not related to patient gender or age,24,25 suggesting that patient-specific factors such as accompanying chronic disease, iron-restricted erythropoiesis, or other factors that normally cause the wide distribution of the hemoglobin level account for the variability in erythropoietic response to erythropoietin.                                View this table: [in this window] [in a new window]   Table 2. Erythropoiesis during blood loss and erythropoietin therapy Studies in patients with the anemia of chronic disease (osteoarthritis26-28 or rheumatoid arthritis29,30) are summarized in Table 3. Red cell volume expansion ranged from 157 to 353 mL (11% to 24%) for endogenous erythropoietin-mediated erythropoiesis and 268 to 673 mL (21% to 44%) with erythropoietin therapy. These erythropoietic responses are indistinguishable from those in patients with anemia from blood loss alone, noted in Tables 1 and 2. A study of 17 patients with inflammatory bowel disease treated with erythropoietin and oral iron therapy demonstrated a similar response, with an estimated 20% increase in red cell volume over that in placebo-treated patients.31                                View this table: [in this window] [in a new window]   Table 3. Erythropoietin and erythropoiesis in patients with anemia of chronic disease     Iron-restricted erythropoiesis and iron therapy Top Abstract Introduction Blood loss anemia through... Iron-restricted erythropoiesis... Anemia of chronic renal... Laboratory evaluation Clinical management: iron... Conclusion References Blood loss and the endogenous erythropoietin response Erythropoiesis in response to aggressive autologous phlebotomy through endogenous erythropoietin has been estimated to increase by approximately 3 times.16,32 As illustrated in Figure 1, panel A, no relationship exists between basal iron stores and this magnitude of erythropoiesis, suggesting that serum iron and transferrin saturation for erythron requirements are adequately maintained by storage iron.13-16 Little or no benefit to oral iron supplementation was found in 2 studies,13,33 whereas a third study12 found some benefit (Table 1). Intravenous iron supplementation is of no value in enhancing erythropoiesis under these conditions.12,13 View larger version (25K): [in this window] [in a new window]   Fig 1. Initial storage iron and red blood cell volume expansion. (A) Relationship between initial storage iron (mg) and red blood cell volume expansion (mL/kg) in patients undergoing aggressive phlebotomy, without erythropoietin therapy. Based on data from reference 32. Linear regression analysis (not shown) demonstrated no significant correlation (r = 0.06; P = .67). (B) Relationship between initial storage iron (mg) and red blood cell volume expansion (mL/kg) in patients undergoing aggressive phlebotomy, with erythropoietin therapy. Linear regression analysis demonstrated a significant correlation (r = 0.6; P = .02). Reprinted with permission.32 Blood loss and erythropoietin therapy With enhanced erythropoiesis during erythropoietin therapy, iron-restricted erythropoiesis occurs even in patients with measurable storage iron (Figure 1B). Despite an 8-fold increase in gastrointestinal iron absorption,34 serum ferritin and transferrin saturation levels decline up to 50% with erythropoietin therapy.35 A 4-fold increase in erythropoietic activity is accompanied by declining reticulocyte counts and the appearance of hypochromic red cells by the second week of erythropoietin therapy.23,36 The superior erythropoietic response in a patient with hemochromatosis further suggests iron-restricted erythropoiesis in patients treated with erythropoietin (Table 2).23 Basal red cell precursor mass is also a limiting factor. Half-maximal hemoglobin synthesis can be achieved by as few as 50 molecules of erythropoietin per target cell. This means that the high levels of serum erythropoietin present initially after parenteral injection are not entirely used for erythropoiesis.37-39 The biologic response is, therefore, maximal at lower levels than the erythropoietin concentration required to saturate all erythropoietin-binding sites. Consistent with this, reticulocyte responses in healthy subjects peak after a single erythropoietin dose of 1800 U/kg,40 and storage iron is mobilized more effectively after multiple-dose regimens than after single-dose regimens.41 A 72-hour interval between erythropoietin administrations is superior to a 24-hour interval.42 Erythropoietin therapy stimulates the gradual expansion of erythroblast mass,43 so that acute demands for erythropoiesis are met by an influx from pre-erythroid colony forming unit (CFU-E) pools, and chronic demands (eg, chronic hemolytic anemia) are met by an amplified pool of later erythroid precursors. Expansion and maturation of erythroid precursor cells are, therefore, limiting factors in the erythropoietic response to acute blood loss anemia and in treatment strategies using larger erythropoietin dosages. In a study of escalating (400%) erythropoietin dose administered to patients undergoing aggressive phlebotomy, the marrow erythropoietic index increased from 2.9 times (with endogenous erythropoietin stimulation) to 3.6 times over basal rates of erythropoiesis, representing only a 58% increase in erythropoiesis (Figure 2). Emerging growth factors, such as novel erythropoiesis-stimulating protein,44 may have different pharmacokinetics regarding dose and response related to longer plasma residence time and erythron expansion. View larger version (21K): [in this window] [in a new window]   Fig 2. Erythropoietic response, as reflected in the bone marrow erythropoietic index, in 4 cohorts of autologous donors treated with placebo or escalating doses of erythropoietin therapy. (U/kg, given for 6 doses over 3 weeks.) Erythropoietic response (mL/kg per day) was estimated for each treatment group, according to the formula: bone marrow erythropoietic index = [RBC expansion] + [baseline RBC production] = [baseline RBC production]. Based on data from Goodnough et al.16 Blood loss and iron therapy Whether iron-restricted erythropoiesis is clinically important in patients with blood loss anemia is detailed in Table 4.27,32 No differences in erythropoiesis stimulated by endogenous erythropoietin alone were seen between patients with or without measurable storage iron, in which the mean red blood cell expansion was 20% and 22%, respectively, in one study32 and 23% and 24%, respectively, in another study.27 When patients were administered erythropoietin therapy, those without measurable storage iron had reductions in erythropoiesis compared to patients with storage iron that reached statistical significance in one study (P < .05)27 but not another (P = .07).32 These studies indicate that oral iron supplementation is sufficient for endogenous erythropoietin-mediated RBC expansion but may not be sufficient to prevent iron-restricted erythropoiesis during erythropoietin therapy.                                View this table: [in this window] [in a new window]   Table 4. Erythropoietin and erythropoiesis in patients with or without iron deficiency Intravenous iron can allow up to a 5-fold erythropoietic response to significant blood loss anemia in healthy persons.3,45 A greater rate of hemoglobin production is probably not possible unless red marrow expands into yellow marrow space, as is seen in hereditary anemias.2,45 One limitation to intravenous iron therapy in patients not undergoing erythropoietin therapy may be that much of the administered iron is transported into the reticuloendothelial system as storage iron, where it is less readily available for erythropoiesis.46 For iron-deficient patients, 50% of intravenous iron is incorporated into hemoglobin within 3 to 4 weeks,47 whereas for patients with anemia of chronic disease or renal failure, intravenous iron is less rapidly mobilized from the reticuloendothelial system.48 The value of intravenous iron administration in patients undergoing erythropoietin therapy is not established. In one clinical trial,26 significantly greater erythropoietic responses were seen with intravenous iron therapy than with oral iron supplementation only (Table 3). However, a recent study28 found no difference in red cell production between oral iron and intravenous iron therapy in patients before orthopedic surgery. Another study found that intravenous iron supplementation was not accompanied by a corresponding erythropoietic response to increasing doses of erythropoietin therapy; a 2-fold increase in erythropoietin dose was associated with only a 32% increase in red cell production,22 similar to the dose-response relationship using oral iron supplementation.16 Intravenous iron administered to normal subjects treated with erythropoietin abolished the marked reduction in serum ferritin and increased the reticulocyte hemoglobin content (a measure in g/L of the hemoglobin contained in all reticulocytes); however, the total number of reticulocytes generated in 8 days after therapy was not affected.49 Finally, perisurgical exposure to allogeneic blood is not different for autologous blood donors with or without measurable storage iron, regardless of oral27,32 or intravenous iron28 administration. The current status of intravenous iron therapy in patients with blood loss anemia is summarized in Table 5.50-55                                View this table: [in this window] [in a new window]   Table 5. Current status of intravenous iron therapy     Anemia of chronic renal failure or chronic disease Top Abstract Introduction Blood loss anemia through... Iron-restricted erythropoiesis... Anemia of chronic renal... Laboratory evaluation Clinical management: iron... Conclusion References The success of erythropoietin therapy in correcting the anemia of chronic renal failure has led to substantial clinical experience and knowledge in erythropoietin, iron metabolism, and erythropoiesis in this setting.52,56 A distinguishing characteristic of the anemia in patients undergoing chronic renal dialysis is the presence of a normal mean corpuscular volume (MCV) in 85% of the patients and hypochromia in 96% of the patients.57 Hyporesponsiveness to erythropoietin therapy is a common phenomenon in these patients58,59 because of a variety of co-morbid conditions, particularly aluminum toxicity and iron deficiency. Anemic patients undergoing dialysis may have suboptimal responses to oral iron therapy for several reasons. Under basal conditions, their absorption levels of food iron and therapeutic oral iron are similar to levels in normal subjects.60 During erythropoietin therapy, the absorption of iron increases as much as 5 times.61 Nevertheless, external iron loss, including loss from hemodialysis and blood testing, exceed gastrointestinal iron absorption.52 Poor compliance because of gastrointestinal symptoms is problematic, and significantly reduced iron absorption may occur with some newer iron formulations.62 Iron-restricted erythropoiesis is evident by clinical responses to ascorbate supplementation, thought to facilitate the release of iron from reticuloendothelial stores and increased iron use by erythrons,59 and by the success of intravenous iron therapy in reducing erythropoietin dosage.56 Because anemia is a determinant of life expectancy in patients on dialysis for chronic disease,57,63 intravenous iron administration has become standard therapy for many patients receiving erythropoietin therapy.64 Dialysis patients treated with intravenous iron (100 mg twice a week) achieved a 46% reduction in erythropoietin dosage, required to maintain hematocrit levels between 30% and 34%, compared with patients supplemented with oral iron.56 In a study of patients with chronic renal failure but not on dialysis,53 two thirds of patients who were unresponsive to oral iron responded to weekly intravenous iron therapy. Improved erythropoiesis occurred despite initial serum ferritin levels as high as 400 µg/L,65 indicating that biochemical markers of storage iron are not helpful in evaluating iron-restricted erythropoiesis. The effect of intravenous iron therapy in patients with the anemia of chronic disease undergoing erythropoietin therapy is shown in Table 3. Patients with osteoarthritis and measurable storage iron doubled their red cell expansion, from a range of 21% to 22% (with oral iron) to 40% to 43% with intravenous iron.26 Intravenous iron therapy in iron-deficient patients with inflammatory bowel disease also resulted in improved responses to erythropoietin therapy55 compared with a similar patient group who received oral iron supplementation.31 The clinical response to intravenous iron may be attributed to the salutary effect of erythropoietin on iron mobilization from the reticuloendothelial system into red cell precursors.66 The risk/benefit profile of intravenous iron is controversial in anemic patients on renal dialysis59,63,64,67 and in patients with anemia of chronic disease.68 Nevertheless, clinical settings in which the effect of intravenous iron therapy on erythropoiesis is beneficial, not beneficial, or undefined (investigational) are summarized in Table 5.     Laboratory evaluation Top Abstract Introduction Blood loss anemia through... Iron-restricted erythropoiesis... Anemia of chronic renal... Laboratory evaluation Clinical management: iron... Conclusion References Iron, transferrin, and transferrin saturation The diagnosis of iron deficiency is traditionally based on a combination of parameters, including iron metabolism and hematologic indices.69-73 Technical and biologic issues limit the usefulness of these assays in the clinical setting,74-78 and the value of iron, transferrin, and transferrin saturation is limited to uncomplicated iron deficiency. During repeated phlebotomy, there is little change in iron levels until iron stores are exhausted, after which iron declines to below 50 µg/dL.69 Once iron stores are depleted, transferrin increases linearly to approximately 400 µg/L. Transferrin saturation, therefore, falls below 16% only when iron stores are exhausted, in contrast to erythropoietin therapy-induced erythropoiesis, in which iron saturation falls even in the presence of storage iron.71 Hence, the detection of iron-restricted erythropoiesis during erythropoietin therapy6,35,41,71-73 poses additional challenges. Ferritin Ferritin is widely used as a marker of iron storage,79-81 with a log relationship between serum ferritin and liver iron (measured with magnetic spectrophotometry) and with a cutoff of 15 µg/L indicating absent iron stores in normal persons.82-84 However, 1 study found that 25% of women with no stainable bone marrow iron had serum ferritin levels above the 15 µg/L cutoff.85 Ferritin levels are elevated in conditions such as hyperthyroidism, inflammation/infection, hepatocellular disease, malignancies, alcohol consumption, and oral contraceptives.86 A cutoff level of 30 µg/L87 to 40 µg/L88 for anemic patients is desirable to provide optimal diagnostic efficiency (positive predictive values of 92% to 98%, respectively), even without clinical evidence of infection or inflammation. Subjects treated with erythropoietin exhibit a rapid decrease in ferritin to levels 50% to 75% below baseline.34,49,89 Ferritin also decreased rapidly after intravenous iron administration in normal subjects treated with erythropoietin.49 Under these conditions, ferritin most likely reflects the iron content of a smaller, more labile pool in equilibrium with erythropoietic compartment and storage iron. Many patients have underlying disorders with "inappropriately high" serum ferritin levels. Two thirds of patients on renal dialysis respond to intravenous iron therapy; their mean ferritin levels of 94 µg/L and mean transferrin saturations of 22% are no different from those of patients not responsive to intravenous iron.65 This has led to suggested guidelines54 and algorithms90 for anemic patients with renal failure, in whom ferritin levels of less than 200 µg/L alone or less than 400 µg/L with a transferrin saturation less than 20% are used to determine the need for intravenous iron therapy90; only at transferrin saturations greater than 50% or ferritin levels in excess of 800 µg/L are these patients considered unlikely to benefit from iron therapy.54 Among patients with the anemia of cancer who are treated with erythropoietin, ferritin levels greater than 400 µg/L correctly predicted lack of response in 88%, whereas levels less than 400 µg/L correctly predicted response in 75%.91 However, several studies have failed to show a role for ferritin in predicting response to erythropoietin or in identifying functional iron deficiency in patients with cancer-related anemia.92-94 It is reasonable to assume that ferritin levels lower than 200 µg/L would predict response to intravenous iron in most patients receiving erythropoietin. Erythrocyte ferritin and zinc protoporphyrin Some studies have advocated a role for erythrocyte ferritin, rather than serum ferritin, in detecting iron deficiency in patients with anemia of chronic disorders.95-98 However, this difficult assay is insensitive to dynamic changes and becomes abnormally low only after most of the red cell population has been replaced by iron-deficient erythrocytes. A similar limitation of the zinc protoporphyrin measurement is that a significant proportion of the red cell pool must contain new red blood cells produced under iron-restricted conditions.99 Furthermore, the zinc protoporphyrin measurement is sensitive to interference by drug and plasma components.100 Zinc protoporphyrin, therefore, has little value in identifying iron-restricted erythropoiesis.101 Erythrocyte indices Erythropoietin therapy in patients on dialysis is associated with the progressive appearance of hypochromic, microcytic erythrocytes.102 Values exceeding 10% (normally less than 2.5%) are compatible with iron-restricted erythropoiesis.54 Hypochromic erythrocytes are observed when erythropoietin is administered to normal subjects undergoing multiple phlebotomies,89 but not when it is administered to a patient with hereditary hemochromatosis treated similarly.23 Erythrocyte indices are helpful for monitoring iron status and the need for iron supplementation during erythropoietin therapy for the anemia of chronic renal failure.103-106 Hypochromic erythrocytes also increase in patients with increased numbers of normal reticulocytes and young red cells. Therefore, the value of this assay has been questioned.107-109 Reticulocyte parameters Because reticulocytes are normally released from the marrow 18 to 36 hours before their final maturation into erythrocytes, they provide a real-time assessment of the functional state of erythropoiesis. However, in the early phases of stimulated erythropoiesis, changes in absolute reticulocyte counts reflect the release from marrow of immature reticulocytes rather than the true expansion of erythropoiesis.45,48,110,111 It has been suggested that a response to erythropoietin can be assessed by measuring hemoglobin and reticulocyte counts after 4 weeks of therapy; a change in hemoglobin level by more than 1.0 g/dL or a change in absolute reticulocyte count by more than 40 × 109/L could indicate that the patient is a responder to erythropoietin therapy.93,112,113 Flow cytometric analysis of reticulocytes allows precise measurements of reticulocyte cell volume (MCVr), hemoglobin concentration (CHCMr), and hemoglobin content (CHr).114,115 In normal subjects, erythropoietin therapy induces an increase in MCVr and a decrease in CHCMr.43 Normal subjects treated with erythropoietin with baseline serum ferritin levels greater than 100 µg/L produce almost no hypochromic reticulocytes. Iron-restricted erythropoiesis is detected at an earlier stage if reticulocyte parameters rather than red cell indices are used.89,111,116,117 CHr has been studied in patients on dialysis. CHr demonstrated 100% sensitivity and 80% specificity and was a more accurate predictor of response to iron therapy than serum ferritin, transferrin saturation, or percentage hypochromic erythrocytes.107 Another study showed that a baseline CHr of less than 28 pg had 78% sensitivity and 71% specificity for detecting iron-restricted erythropoiesis, compared with 50% and 39% for traditional biochemical measures.118 In dialysis patients treated with erythropoietin, CHr increases during intravenous iron therapy, indicating value as an early indicator of iron-restricted erythropoiesis,119 even with normal serum ferritin or transferrin saturation.120 Measurements of total reticulocyte hemoglobin, an integrated index derived from the absolute reticulocyte count and the CHr,121 showed that reticulocyte-hemoglobin levels are much higher in subjects treated with intravenous iron.49 Moreover, in patients undergoing cardiac surgery, the administration of intravenous iron along with erythropoietin therapy abolishes the production of hypochromic reticulocytes, and CHr remains within the normal range.122 A recent study123 concluded that CHr was the strongest predictor of iron deficiency in children, and it should be considered an alternative to standard iron studies for the diagnosis of iron deficiency. Another reticulocyte parameter now provided by automated analyzers is the immature reticulocyte fraction. Because it is sensitive to leukocyte interference124 and is difficult to standardize,125,126 its clinical use has been limited. The immature reticulocyte fraction reflects the degree of erythropoiesis, but it is not indicative of iron-restricted erythropoiesis.127,128 Transferrin receptor The soluble transferrin receptor (TfR) is derived primarily from red cell precursor normoblasts129 and provides an estimate of the erythroid compartment mass. Both enhanced erythropoiesis and iron deficiency elevate TfR.129,130 Endogenous erythropoietin-mediated erythropoiesis through phlebotomy minimally influences TfR until iron-restricted erythropoiesis occurs, as illustrated in Figure 3.69 Serum ferritin is the most sensitive and specific index of iron status when there are residual iron stores, whereas TfR is most sensitive in the presence of iron-restricted erythropoiesis.88 View larger version (17K): [in this window] [in a new window]   Fig 3. Endogenous erythropoietin-mediated erythropoiesis by phlebotomy minimally influences serum transferrin receptor (TfR) until iron-restricted erythropoiesis occurs. Serial determinations of TfR during phlebotomy in 3 subjects with initial iron stores of 107 mg (), 335 (), and 1,102 mg (). Reprinted with permission.69 In a study of 43 healthy, nonanemic adult women, 17 (40%) had significant changes in TfR in response to oral iron therapy, indicating the presence of subclinical iron deficiency.131 In another study, 25% of patients undergoing routine ferritin tests, who were also studied for TfR measurements, were categorized as iron deficient by TfR (more than 2.8 mg/L) but not by ferritin (more than 12 µg/L).88 These values could represent iron-replete persons with increased erythropoiesis or iron-deficient patients with acute-phase increases of ferritin values. The clinical usefulness of the TfR may be limited to the subset of ill patients in whom iron deficiency is suspected but whose ferritin values are normal or raised,88 seen commonly in the anemia of chronic disease; numerous studies69,87,88,132-134 have shown TfR to be of value in differentiating iron-deficiency anemia (in which TfR is usually increased) from the anemia of chronic disease (in which TfR is usually normal). Meaningful comparisons of studies of TFR are difficult because of differences resulting from the reagents used. The value of TfR in predicting the response to erythropoietin therapy and the adequacy of iron availability is modest. Although lower baseline or low-normal TfR levels predict the initial response to erythropoietin therapy in patients on dialysis,135 other studies have shown little predictive value for this assay in patients receiving erythropoietin because serum TfR values above normal are observed in iron deficiency and during erythropoietin-induced expansion of erythropoietic activity.136 The combination of TfR measurements, serum ferritin, and automated reticulocyte counts may be predictive of an erythropoietic response to increased erythropoietin dosage or of the need to ensure adequate iron replacement, such as by the intravenous administration of iron.137,138 Further studies are required to delineate the clinical usefulness of TfR measurements in these settings. Erythropoietin assay A classification of anemias has been proposed around the concept of adequate or inadequate erythropoietin response to degree of anemia139-141; patients with iron-deficiency or chronic hemolytic anemia would comprise the reference populations.142-144 The correlation between the percentage of patients showing an "inadequate" erythropoietin response to anemia and the percentage of patients responding to erythropoietin therapy (according to the author's criteria) can be illustrated (Figure 4) for several diseases, with a range in response to myelodysplastic syndromes,145 multiple myeloma,146 and rheumatoid arthritis.147 View larger version (16K): [in this window] [in a new window]   Fig 4. Correlation between the percentage of patients showing inadequate erythropoietin response to anemia and the percentage responding to erythropoietin therapy (according to the authors' criteria). Numbers are derived directly or are calculated from reported data. ARF, anemia of renal failure; RA, anemia of rheumatoid arthritis; HIV, anemia in patients with human immunodeficiency virus; MM, anemia in multiple myeloma; Cancer, anemia of cancer; MDS/MMM, anemia in myelodysplastic syndromes and myelofibrosis with myeloid metaplasia. Reprinted with permission.141 There are several problems with the use of erythropoietin levels in the management of patients. The interpretation of an erythropoietin level must take into account the degree of anemia at the time of measurement. Commercial assay results do not take this into consideration; hence, clinicians must have some familiarity with mathematical corrections, such as observed/predicted ratios.141 A retrospective analysis of erythropoietin therapy in anemic patients with cancer not undergoing chemotherapy148 found that pre-treatment erythropoietin levels of less than 200 mU/mL were correlated with red cell response to erythropoietin therapy. Subsequent analyses, however, have found that erythropoietin levels are not predictive for response in cancer patients undergoing chemotherapy.149,150 Because almost all anemic patients with cancer or on renal dialysis have erythropoietin levels that are inadequate for the degree of anemia,141 measuring erythropoietin levels is not useful in these settings. Furthermore, guidelines recommend that erythropoietin therapy be instituted before hemoglobin levels fall below 10 g/L, a level at which interpretation of erythropoietin level is not valid.141 The erythropoietin assay may be most useful as a determinant of response to therapy in certain patients, such as those with myelodysplasia.145 The proliferative state of bone marrow erythroid cells affects erythropoietin levels,151 as does iron status,152 hemolysis,153 and chemotherapy-induced endothelial damage.154 TfR has helped in the understanding of the relationship between hemoglobin level and serum erythropoietin. As illustrated in Figure 5, a patient with pure red cell aplasia and a markedly elevated erythropoietin level was administered erythropoietin therapy for 4 weeks. Before hemoglobin level increased, the erythropoietin level decreased because erythroid activity measured by TfR reappeared. The increased plasma clearance of erythropoietin is probably related to an influx of early RBC precursors into CFU-E from primitive erythroid burst-forming units (BFU-E). CFU-E has a higher concentration of erythropoietin receptors than BFU-E,39 so late BFU-E through the proerythroblast stage defines the narrow window of erythroid cellular compartment that is erythropoietin responsive.151 View larger version (23K): [in this window] [in a new window]   Fig 5. Time course of hemoglobin (Hb) level, serum erythropoietin level (sEpo), and serum transferrin receptor (sTfR) in a patient with pure red cell aplasia (PRCA) responding to treatment. The patient was treated with erythropoietin at a dose of 150 U/kg per day subcutaneously, 5 days a week; dosage was reduced to 3 weekly administrations when Hb level achieved 12 g/dL, and treatment was discontinued after 8 weeks. Reprinted with permission.151 A recent study of anemic children with systemic-onset juvenile chronic arthritis found that erythropoietin levels were appropriate for the degree of anemia. Variable iron status, measured by TfR levels, accounted for variations in hemoglobin levels, and intravenous iron therapy resulted in the normalization of TfR levels.155 Another study in children with cancer found that TfR levels were inappropriately low for the degree of anemia, and a highly significant correlation between the logarithms of erythropoietin and hemoglobin levels was identified.156 The report concluded that anemia in children with cancer results from decreased erythropoietic activity, in contrast to anemia in adults with cancer.142 The anemia of chronic inflammatory disease is particularly multifactorial, caused not only by impaired erythropoietin response but also by defective iron supply to the erythron, along with inflammatory cytokine-mediated suppression of the erythropoietic response to erythropoietin.157,158 To effectively evaluate erythroid activity, an assay of TfR and mathematical correction of the erythropoietin level would be necessary,151 but this is not practical for clinical evaluation and patient management. In summary, pre-therapy laboratory evaluation of erythropoietin, iron, or erythropoiesis in anemic patients may no longer be always appropriate. Rather, the epidemiology (ie, clinical setting) of the anemia may suggest a therapeutic trial of iron or erythropoietin therapy, with post-therapy laboratory evaluation determining the response. One example of this approach is the empiric use of oral iron therapy in otherwise well anemic, menstruating women, in which a follow-up blood count may serve as the sole laboratory assay. A second example is patients with chronic renal failure who remain anemic despite erythropoietin therapy and in whom an empiric trial of intravenous iron is recommended despite apparent laboratory evidence of storage iron. Follow-up transferrin saturations, serum ferritin, and blood counts then determine when intravenous iron therapy can be modified or withdrawn.54 Hematologic parameters are emerging as promising alternatives to biochemical markers in evaluating iron-restricted erythropoiesis.     Clinical management: iron therapy strategies Top Abstract Introduction Blood loss anemia through... Iron-restricted erythropoiesis... Anemia of chronic renal... Laboratory evaluation Clinical management: iron... Conclusion References With significant on-going iron losses, oral iron supplementation is not enough to correct iron-deficient erythropoiesis. Patients on renal dialysis have such blood losses, and intravenous iron therapy allows the correction of anemia through the use of lower erythropoietin doses.54,159 Another role for intravenous iron therapy is in bloodless medical treatment and bloodless surgery for patients who decline blood transfusions because of religious beliefs.50 These patients include pregnant women and patients with dysfunctional uterine bleeding who are scheduled for hysterectomy.51 Intravenous iron therapy has been closely scrutinized for risks and adverse events. Imferon (iron dextran BP, Merrill-Dow, Cincinnati, OH) was previously approved for parenteral use.160 This product was associated with a 0.6% risk of anaphylactoid reactions and a 1.7% risk of severe serum sickness-like reactions characterized by fever, arthralgias, and myalgias.161 Delayed reactions of up to 30% and severe reactions of 5.3% were subsequently described. They were attributed to changes in manufacturing processes,162 and this product was withdrawn from use. InFed (iron dextran USP; Schein Pharm, Florham Park, NJ) has been approved for parenteral (intramuscular or intravenous) use in the United States. InFed (Schein Pharm) administered intravenously during dialysis is associated with significant adverse reactions in 4.7% of patients, of which 0.7% are serious or life threatening and another 1.7% are characterized as anaphylactoid.163 The prevalence of these reactions does not differ among patients receiving low-dose (100 mg) or higher-dose (250-500 mg) infusions.164 A recent review reported 196 incidences of allergy/anaphylaxis from iron dextran between 1976 and 1996, of which 31 (15.8%) were fatal.165 Safety aspects of parenteral iron dextran, ferric gluconate, and iron saccharate have been scrutinized.166-168 Iron saccharate is available in Europe but not in the United States. Ferric gluconate has been available in Europe for more than 20 years and was approved for intravenous use in the United States in 1999 (Ferrlecit; Schein Pharm) in patients on renal dialysis. Dosage is limited to 125 mg infused over 1 hour at each administration. The number of allergic reactions (3.3 episodes per million doses) is lower than that from iron dextran (8.7 episodes per million doses), and the safety profile is substantially better; among 74 severe adverse events reported from 1976 to 1996, there were no deaths.165 Adverse events associated with ferric gluconate include hypotension, rash, and chest or abdominal pain, with an incidence of 1.3% for serious reactions.170,171 Intravenous iron therapy can cause a clinical syndrome (nausea, facial reddening, and hypotension) that may be attributed to acute iron toxicity caused by oversaturation (more than 100%) of transferrin172 or nonspecific drug toxicity.173 The increased erythropoietic effect (4.5 to 5.5 times basal) of intravenous iron dextran (with an estimated half-life of 60 hours) is transient and lasts 7 to 10 days, after which the remaining iron is sequestered in the reticuloendothelial system and erythropoiesis returns to basal rates.3 Iron measurements and intravenous iron therapy are optimal at 2-week intervals. A dose-response relationship between erythropoietin and erythropoiesis that is affected favorably by intravenous iron has important implications for erythropoietin dosage and cost.174 The current total recommended erythropoietin dose for patients scheduled for elective surgery175 ranges from 1800 U/kg176 to 4200 U/kg,177,178 which for a 70-kg patient would cost $1300 to $3000.179 However, an economic analysis of erythropoietin therapy in patients undergoing orthopedic surgery concluded that even the lower recommended dosage is not cost effective.180 Intravenous iron may potentiate the erythropoietic response in erythropoietin therapy by improving functional iron deficiency. A multicenter trial in dialysis patients, designed to achieve normal (more than 42%) or low (more than 30%) hematocrits with a combination of erythropoietin therapy and intravenous iron (dextran USP) supplementation, was halted because of increased mortality in the high hematocrit cohort.63 These patients experienced a decline in dialysis adequacy and received intravenous iron in greater quantities than those in the low hematocrit group. Debated links between iron stores and morbidity or mortality rates include a predisposition to infection,181,182 increased death from infection183 in dialysis patients, and detrimental coronary outcomes in men.184-186 An accompanying editorial187 to a U.S. study of ferric gluconate170 concluded that its role in the management of anemia from renal disease was unclear until its relative efficacy, tolerability, and cost effectiveness is established. However, another editorial64 accompanying the target hematocrit study63 concluded that for patients with anemia of chronic renal disease, intravenous iron is recommended to reach target hematocrit goals of 33% to 36%. The current status of intravenous iron therapy for patients who are unresponsive to oral iron or in whom it is malabsorbedalong with opportunities for investigationare presented in Table 5.     Conclusion Top Abstract Introduction Blood loss anemia through... Iron-restricted erythropoiesis... Anemia of chronic renal... Laboratory evaluation Clinical management: iron... Conclusion References The development of new laboratory methods to assess iron-restricted erythropoiesis, along with clinical trials of blood phlebotomy and erythropoietin therapy, have furthered our understanding of the relationship between erythropoietin, iron, and erythropoiesis. Hematologic indices and reticulocyte parameters measured by new automated counters hold promise in the evaluation of iron-restricted erythropoiesis, but more studies are needed to define their role with iron and erythropoietin therapy. Erythropoietin and transferrin receptor assays are valuable tools for clinical research, but their roles in routine clinical practice remain undefined. The availability of a safer intravenous iron preparation allows an opportunity to study its value in patients with blood loss anemia, particularly those undergoing erythropoietin therapy. Given the low prevalence but potential side effects, the use of intravenous iron for patients other than those with chronic renal failure and those who decline blood because of religious beliefs must be defined by controlled clinical trials.     Footnotes Submitted July 30, 1999; accepted February 24, 2000. Reprints: Lawrence T. Goodnough, Division of Laboratory Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Box 8118, St. Louis, MO 63110; e-mail: goodnough{at}labmed.wustl.edu. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Blood loss anemia through... Iron-restricted erythropoiesis... Anemia of chronic renal... Laboratory evaluation Clinical management: iron... Conclusion References 1. Finch CA. Erythropoiesis, erythropoietin, and iron. Blood. 1982;60:1241-1246[Free Full Text]. 2. Crosby WH. The metabolism of hemoglobin and bile pigment in hemolytic disease. Am J Med. 1955;18:112-122 3. Hillman RS, Henderson PA. Control of marrow production by the level of iron supply. J Clin Invest. 1969;48:454-460. 4. Crosby WH. Treatment of haemochromatosis by energetic phlebotomy: one patient's response to the letting of 55 liters of blood in 11 months. Br J Haematol. 1958;4:82-88. 5. Coleman PH, Stevens AR, Dodge HT, Finch CA. Rate of regeneration after blood loss. Arch Int Med. 1953;92:341-348[Abstract/Free Full Text]. 6. Finch CA. Perspectives in iron metabolism. N Engl J Med. 1982;25:1520-1528. 7. Menitove J, ed. Standards for Blood Banks and Transfusion Services. Vol 7. 19th ed. Bethesda, MD: American Association of Blood Banks; 1999:10. 8. Goodnough LT, Brittenham G. Limitations of the erythropoietic response to serial phlebotomy. implications for autologous blood predeposit programs. J Lab Clin Med. 1990;115:28-35[Medline] [Order article via Infotrieve]. 9. Kickler TS, Spivak JL. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. JAMA. 1988;260:65-67[Abstract/Free Full Text]. 10. Goodnough LT, Mercuriali F. Compensatory erythropoiesis during routine autologous blood donation. Transfusion. 1998;38:613-614[Medline] [Order article via Infotrieve]. 11. Kasper SM, Gerlich W, Buzello W. Preoperative red cell production in patients undergoing weekly autologous blood donation. Transfusion. 1997;37:1058-1062[Medline] [Order article via Infotrieve]. 12. Kasper SM, Lazansky H, Stark C, Klimek M, Laubinger R, Börner Y. Efficacy of oral iron supplementation is not enhanced by additional intravenous iron during autologous blood donation. Transfusion. 1998;38:764-770[Medline] [Order article via Infotrieve]. 13. Weisbach V, Skoda P, Rippel R, et al. Oral or intravenous iron as an adjunct to autologous blood donation in elective surgery: a randomized, controlled study. Transfusion. 1999;39:465-472[Medline] [Order article via Infotrieve] 14. Goodnough LT, Rudnick S, Price TH, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med. 1989;321:1163-1168[Abstract]. 15. Goodnough LT, Price TH, Rudnick S, Soegiarso RW. Preoperative red blood cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion. 1992;32:441-445[Medline] [Order article via Infotrieve]. 16. Goodnough LT, Price TH, Friedman KD, et al. A phase III trial of recombinant human erythropoietin therapy in non-anemic orthopedic patients subjected to aggressive autologous blood phlebotomy: dose, response, toxicity, efficacy. Transfusion. 1994;34:66-71[Medline] [Order article via Infotrieve]. 17. Brecher MA, Monk TG, Goodnough LT. A standardized method for calculating blood loss. Transfusion. 1997;37:1070-1074[Medline] [Order article via Infotrieve] 18. Goodnough LT, Bravo J, Hsueh Y, Keating L, Brittenham GM. Red blood cell volume in autologous and homologous blood units: implications for risk benefit assessment for autologous blood "crossover" and directed blood transfusion. Transfusion. 1989;29:821-822[Medline] [Order article via Infotrieve]. 19. Goodnough LT, Price TH, Parvin CA, et al. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haematol. 1994;87:695-699[Medline] [Order article via Infotrieve]. 20. Adamson JW. The erythropoietin/hematocrit relationship in normal and polycythemic man: implications of marrow regulation. Blood. 1968;32:597-609[Abstract/Free Full Text]. 21. Sans T, Bofill C, Joven J, et al. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery. Transfusion. 1996;36:822-826[Medline] [Order article via Infotrieve]. 22. Mercuriali F, Inghilleri, Biffi E, Colotti MT, Vinci A, Oriani G. Epoietin alfa in low hematocrit patients to facilitate autologous blood donation in total hip replacement: a randomized, double-blind, placebo-controlled, dose-ranging study. Acta Haematol. 1998;100:69-76[Medline] [Order article via Infotrieve]. 23. Brugnara C, Chambers LA, Malynn E, Goldberg MA, Kruskall MS. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood. 1993;81:956-964[Abstract/Free Full Text]. 24. Goodnough LT, Verbrugge D, Marcus RE, Goldberg V. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell expansion. J Am Coll Phys. 1994;179:171-176. 25. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med. 1995;126:57-64[Medline] [Order article via Infotrieve]. 26. Mercuriali F, Zanella A, Barosi G, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion. 1993;33:55-60[Medline] [Order article via Infotrieve]. 27. Price TH, Goodnough LT, Vogler WR, et al. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion. 1996;36:29-36[Medline] [Order article via Infotrieve]. 28. Megens JGN, Olijhoek G, Ziekenhuis V, Musto P, Nogarin L. Comparison of efficacy of oral versus intravenous iron supplementation with epoietin alfa treatment in arthroplasty patients. Br J Anaesthesiol [abstract]. 1999;82(suppl):82. 29. Goodnough LT, Marcus RE. The erythropoietic response to erythropoietin therapy in patients with rheumatoid arthritis. J Lab Clin Med. 1997;130:381-386[Medline] [Order article via Infotrieve]. 30. Mercuriali F, Inghilleri G, Biffi E, et al. Comparison between intravenous and subcutaneous recombinant human erythropoietin (epoietin alfa) administration in presurgical autologous blood donation in anemic rheumatoid arthritis patients undergoing major orthopedic surgey. Vox Sang. 1997;72:93-100[Medline] [Order article via Infotrieve]. 31. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med. 1996;334:619-623[Abstract/Free Full Text]. 32. Goodnough LT, Marcus RE. Erythropoiesis in iron-depleted and iron-replete patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang. 1998;75:128-133[Medline] [Order article via Infotrieve]. 33. Biesma DH, Kraaijenhagen RJ, Poortman J, Marx JJM, Van De Wiel A. The effect of oral iron supplementation on erythropoiesis in autologous blood donors. Transfusion. 1992;32:162-165[Medline] [Order article via Infotrieve]. 34. Skikne BS, Cook JD. Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med. 1992;120:746-751[Medline] [Order article via Infotrieve]. 35. Heiss MM, Tarabichi A, Delanoff C, et al. Perisurgical erythropoietin application in anemic patients with colorectal cancer: a double-blind randomized study. Surgery. 1996;119:52-527. 36. Biesma DH, Van De Wiel A, Beguin Y, Kraaijenhagen RJ, Marx JJM. Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy. Eur J Clin Invest. 1994;24:426-432[Medline] [Order article via Infotrieve]. 37. Gurland HJ, Moran J, Samt Leben W, Scigalla P, Wieczorek L. Erythropoietin in renal and non-renal anemia. Contrib Nephrol. 1991;88:215-235. 38. Elandschulz KT, Noyes AN, Rogers O, Boyer SH. Erythropoietin receptors on murine erythroid colony-forming units: natural history. Blood. 1989;73:1476-1475[Abstract/Free Full Text]. 39. Sawanda K, Krantz SB, Sawyer ST, Civin CI. Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells. J Cell Physiol. 1988;137:337-445[Medline] [Order article via Infotrieve]. 40. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinetics and pharmaco dynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther. 1998;64:412-423[Medline] [Order article via Infotrieve]. 41. Rutherford CJ, Schneider TJ, Dempsey H, Kirn DH, Brugnara C, Goldberg MA. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated persurgical setting: the importance of iron availability in optimizing response. Am J Med. 1994;96:139-145[Medline] [Order article via Infotrieve]. 42. Breymann C, Bauer C, Major A, et al. Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers. Br J Haematol. 1996;93:295-301[Medline] [Order article via Infotrieve]. 43. Beguin Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin. Br J Haematol. 1995;89:17-23[Medline] [Order article via Infotrieve]. 44. Vanrenterghem Y, Barany P, Mann J. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or once every other week [abstract]. J Am Soc Nephrol. 1999;10:270A. 45. Hamstra RD, Block MH. Erythropoiesis in response to blood loss in man. J Appl Physiol. 1969;27:503-507[Free Full Text]. 46. Beutler E. The utilization of saccharated Fe59 oxide in red cell formation. J Lab Clin Med. 1958;51:415-419. 47. Wood JK, Milner FA, Pathak UN. The metabolism of iron dextran given as a total dose infusion to iron deficient Jamaican subjects. Br J Haematol. 1968;14:119-129[Medline] [Order article via Infotrieve]. 48. Beamish MR, Davies AG, Eakins JD, Jacobs A, Trevett D. The measurement of reticuloendothelial iron release using iron-dextran. Br J Haematol. 1971;21:617-622[Medline] [Order article via Infotrieve]. 49. Major A, Mathez-Loic F, Rohling R, Gautschi K, Brugnara C. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol. 1997;98:292-294[Medline] [Order article via Infotrieve]. 50. Baron JF. Primum non nocere. In: Baron JF, ed. Transfusion Alternatives in Transfusion Medicine. 1st ed. Chattilon Cedex, France: LM Sante; 1999:3-5. 51. Mays T, Mays T. Intravenous iron dextran therapy in the treatment of anemia occurring in surgical, gynecologic, and obstetric patients. Surg Gynecol Obstet. 1976;143:381-384[Medline] [Order article via Infotrieve]. 52. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41-46[Medline] [Order article via Infotrieve]. 53. Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234-238[Medline] [Order article via Infotrieve]. 54. NFK-DOQI. Clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997;30:S192-S237[Medline] [Order article via Infotrieve]. 55. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn's disease. Ann Int Med. 1997;126:782-787[Abstract/Free Full Text]. 56. Eschbach J, Egrie J, Downing M, Browne JK, Adamson JW. Correction of anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med. 1987;316:73-78[Abstract]. 57. Madore F, Lowrie EG, Brugnara C, et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol. 1997;8:1921-1929[Abstract]. 58. Means RT. Commentary: an anemia of chronic disease, after all? J Invest Med. 1999;47:203-207[Medline] [Order article via Infotrieve]. 59. Tarng DC, Hyang TP, Chen TW, Yang WC. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int. 1999;55:S107-S118. 60. Skikne B, Ahluwalia N, Fergusson B, Chonko A, Cook J. Effects of recombinant human erthropoietin on iron absorption in chronic renal failure [abstract]. Blood. 1998;92:24B. 61. Skikne BS, Cook JD. Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med. 1992;120:746-751. 62. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficiency of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995;25:433-439[Medline] [Order article via Infotrieve]. 63. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared to low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590[Abstract/Free Full Text]. 64. Adamson JW, Eschbach JW. Erythropoietin for end-stage renal disease. N Engl J Med. 1998;339:625-627[Free Full Text]. 65. Taylor JE, Peat N, Porter C, Morgan AG. Regular, low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1079-1083[Abstract/Free Full Text]. 66. Weiss G, Houston T, Kastner S, Johrer K, Grunewald K, Brock JH. Regulation of cellular iron metabolism by erythropoietin: activation of iron-regulatory protein and up regulation transferrin receptor expression in erythroid cells. Blood. 1997;89:680-687[Abstract/Free Full Text]. 67. Eschbach JW, Adamson JW. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int. 1999;55:S35-S43. 68. Weiss G. Iron and anemia of chronic disease. Kidney Int. 1999;55:S12-S17. 69. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood. 1990;75:1870-1876[Abstract/Free Full Text]. 70. Cook JD, Lipschitz DA, Miles LEM, Finch CA. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr. 1974;27:681-687[Abstract]. 71. Cazzola M, Pootrakul P, Bergamaschi G, Huebers HA, Eng M, Finch CA. Adequacy of supply for erythropoiesis: in vivo observations in humans. J Lab Clin Med. 1987;110:734-739[Medline] [Order article via Infotrieve]. 72. Goodnough LT, Price TH, Rudnik S. Iron-restricted erythropoiesis as a limitation to autologous blood donation in the erythropoietin-stimulated bone marrow. J Lab Clin Med. 1991;118:289-296[Medline] [Order article via Infotrieve]. 73. Hastka J, Lasserre JJ, Schwarzbeck A, Reiter A, Hehlmann R. Laboratory tests of iron status: correlation or common sense? Clin Chem. 1996;42:718-724[Abstract/Free Full Text]. 74. Cavill I. Disorders of iron metabolism: diagnostic methods. Clin Haematol. 1982;11:259.273-277. 75. Soldin SJ, Murthy JN, Agarwalla PK, Ojeifo O, Chea J. Pediatric reference ranges for creatine kinase, CKMB, troponin I, iron and cortisol. Clin Biochem. 1999;32:77-80[Medline] [Order article via Infotrieve]. 76. Eckfeldt JH, Witte DL. Serum iron: would analytical improvement enhance patient outcome? Clin Chem. 1994;40:505-507[Free Full Text]. 77. Tietz NW, Rinker AD, Morrison SR. When is a serum iron really a serum iron? The status of serum iron measurements. Clin Chem. 1994;40:546-551[Abstract/Free Full Text]. 78. Gambino R, Dasvarieux E, Orth M, et al. The relation between chemically measured total iron-binding capacity concentrations and immunologically measured transferrin concentrations in human serum. Clin Chem. 1997;43:2408-2412[Abstract/Free Full Text]. 79. Brittenham G, Danish EH, Harris JW. Assessment of bone marrow and body iron stores: old techniques and new technologies. Semin Hematol. 1981;18:194-220[Medline] [Order article via Infotrieve]. 80. Stacy DL, Han P. Serum ferritin measurement and the degree of agreement using four techniques. Am J Clin Pathol. 1992;98:511-515[Medline] [Order article via Infotrieve]. 81. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med. 1974;290:1213-1216. 82. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332:918-922[Abstract/Free Full Text]. 83. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761[Free Full Text]. 84. Pootrakul P, Kitcharoen K, Yansukon P. The effect of erythroid hyperplasia on iron balance. Blood. 1988;71:1124-1129[Abstract/Free Full Text]. 85. Hallberg L, Bengtsson C, Lapidus L, Lindstedt G, Lundberg PA, Hulten L. Screening for iron deficiency: an analysis based on bone-marrow examinations and serum ferritin determinations in a population sample of women. Br J Haematol. 1993;85:787-798[Medline] [Order article via Infotrieve]. 86. Leggett BA, Brown NN, Bryant SJ, Duplock L, Powell LW, Halliday JW. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin Chem. 1990;36:1350-1355[Abstract/Free Full Text]. 87. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89:1052-1057[Abstract/Free Full Text]. 88. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998;44:45-51[Abstract/Free Full Text]. 89. Brugnara C, Colella GM, Cremins JC, et al. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med. 1994;123:660-664[Medline] [Order article via Infotrieve]. 90. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoietin in patients receiving hemodialysis. N Engl J Med. 1998;339:578-583[Abstract/Free Full Text]. 91. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84:1056-1063[Abstract/Free Full Text]. 92. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin lymphoma: dose finding and identification of predictors of response. Blood. 1995;86:4446-4453[Abstract/Free Full Text]. 93. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/Epoetin-a) therapy in cancer patients. Blood. 1995;85:1676-1678[Free Full Text]. 94. Kasper C, Terhaar A, Fossa A, Welt A, Seeber S, Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related anemia. Eur J Haematol. 1997;58:251-256[Medline] [Order article via Infotrieve]. 95. Balaban EP, Sheehan RG, Demian SE, Cox JV, Frenkel EP. Evaluation of bone marrow iron stores in anemia associated with chronic disease: a comparative study of serum and red cell ferritin. Am J Hematol. 1993;42:177-181[Medline] [Order article via Infotrieve]. 96. Galan P, Sangare N, Preziosi P, Roudier M, Hercberg S. Is basic red cell ferritin a more specific indicator than serum ferritin in the assessment of iron stores in the elderly? Clin Chim Acta. 1990;189:156-162. 97. Brunati C, Piperno A, Guastoni C, et al. Erythrocyte ferritin in patients on chronic hemodialysis treatment. Nephron. 1990;54:219-223[Medline] [Order article via Infotrieve]. 98. Caravaca F, Vagace JM, Aparicio A. Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy. Am J Kidney Dis. 1992;20:249-254[Medline] [Order article via Infotrieve]. 99. Siegel RM, LaGrone DH. The use of zinc protoporphyrin in screening young children for iron deficiency. Clin Pediatr. 1994;33:473-479. 100. Hastka J, Lasserre JJ, Schwarzbeck A, Strauch M, Hehlmann R. Washing erythrocytes to remove interferents in measurements of zinc protoporphyrin by front-face hematofluorometry. Clin Chem. 1992;38:2184-2190[Abstract/Free Full Text]. 101. Garrett S, Worwood M. Zinc protoporphyrin and iron-deficient erythropoiesis. Acta Haematol. 1994;91:21-25[Medline] [Order article via Infotrieve]. 102. Macdougall IC, Cavill I, Hulme B, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ. 1992;304:225-226. 103. Macdougall IC. Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens. 1994;3:620-625[Medline] [Order article via Infotrieve]. 104. Macdougall IC. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant. 1998;13:23-27[Free Full Text]. 105. Schaefer RM, Schaefer L. Iron monitoring and supplementation: how do we achieve the best results? Nephrol Dial Transplant. 1998;13:9-12[Abstract/Free Full Text]. 106. Braun J, Lindner K, Schreiber M, Heidler RA, Horl WH. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant. 1997;12:1173-1181[Abstract/Free Full Text]. 107. Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997;52:217-222[Medline] [Order article via Infotrieve]. 108. Horl WH. What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? measurement of hypochromic red blood cells is not the first line procedure to identify the patient with iron deficiency. Nephrol Dial Transplant. 1998;13:850-851[Free Full Text]. 109. Paterakis GS, Laoutaris NP, Alexia SV, et al. The effect of red cell shape on the measurement of red cell volume: a proposed method for the comparative assessment of this effect among various haematological analysers. Clin Lab Haematol. 1994;16:235-245[Medline] [Order article via Infotrieve]. 110. Major A, Bauer C, Breymann C, Huch A, Huch R. Rh-erythropoietin stimulates immature reticulocyte release in man. Br J Haematol. 1994;87:605-608[Medline] [Order article via Infotrieve]. 111. Cazzola M, Ponchio L, Pedrotti C, et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica. 1996;81:434-441[Abstract/Free Full Text]. 112. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 1997;89:4248-4267[Free Full Text]. 113. Brugnara C, Hipp MJ, Irving PJ, et al. Automated reticulocyte counting and measurement of reticulocyte cellular indices: evaluation of the Miles H*3 blood analyzer. Am J Clin Pathol. 1994;102:623-632[Medline] [Order article via Infotrieve]. 114. Buttarello M, Bulian P, Venudo A, Rizzotti P. Laboratory evaluation of the Miles H*3 automated reticulocyte counter: a comparative study with manual reference method and Sysmex R-1000. Arch Pathol Lab Med. 1995;119:1141-1148[Medline] [Order article via Infotrieve]. 115. d'Onofrio G, Chirillo R, Zini G, Caenaro G, Tommasi M, Micciulli G. Simultaneous measurement of reticulocyte and red blood cell indices in healthy subjects and patients with microcytic and macrocytic anemia. Blood. 1995;85:818-823[Abstract/Free Full Text]. 116. Brugnara C. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int J Clin Lab Res. 1998;28:1-11[Medline] [Order article via Infotrieve]. 117. Brugnara C, Zelmanovic D, Sorette M, Ballas SK, Platt O. Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity. Am J Clin Pathol. 1997;108:133-142[Medline] [Order article via Infotrieve]. 118. Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis. 1997;30:912-913[Medline] [Order article via Infotrieve]. 119. Bhandari S, Norfolk D, Brownjohn A, Turney J. Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy. Am J Kidney Dis. 1997;30:814-821[Medline] [Order article via Infotrieve]. 120. Bhandari S, Turney JH, Brownjohn AM, Norfolk D. Reticulocyte indices in patients with end stage renal disease on hemodialysis. J Nephrol. 1998;11:78-82[Medline] [Order article via Infotrieve]. 121. Davis BH, Bigelow N, Ball ED, Mills L, Cornwell GG III. Utility of flow cytometric reticulocyte quantification as a predictor of engraftment in autologous bone marrow transplantation. Am J Hematol. 1989;32:81-87[Medline] [Order article via Infotrieve]. 122. Sowade O, Sowade B, Brilla K, et al. Kinetics of reticulocyte maturity fractions and indices and iron status during therapy with epoetin beta (recombinant human erythropoietin) in cardiac surgery patients. Am J Hematol. 1997;55:89-96[Medline] [Order article via Infotrieve]. 123. Brugnara C, Zurakowski D, DiCanzio J, Boyd T, Platt O. Reticulocyte hemoglobin content to diagnose iron deficiency in children. JAMA. 1999;281:2225-2247[Abstract/Free Full Text]. 124. Villamor N, Kirsch A, Huhn D, Vives-Corrons JL, Serke S. Interference of blood leucocytes in the measurements of immature red cells (reticulocytes) by two different semi- automated flow-cytometry technologies. Clin Lab Haematol. 1996;18:89-94[Medline] [Order article via Infotrieve]. 125. Davis BH, Bigelow NC, Koepke JA, et al. Flow cytometric reticulocyte analysis: multiinstitutional interlaboratory correlation study. Am J Clin Pathol. 1994;102:468-477[Medline] [Order article via Infotrieve]. 126. Davis BH. Report on the ISLH-sponsored immature reticulocyte fraction (IRF) workshop. Lab Hematol. 1997;3:261-263. 127. Biesma DH, Kraaijenhagen RJ, Dalmulder J, Marx JJM, van De Wiel A. Recombinant human erythropoietin in autologous blood donors: a dose-finding study. Br J Haematol. 1994;86:30-35[Medline] [Order article via Infotrieve]. 128. Musto P, Modoni S, Alicino G, et al. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. Haematologica. 1994;79:493-499[Abstract/Free Full Text]. 129. Flowers CH, Skikne BS, Covell AM, Cook JD. The clinical measurement of serum transferrin receptor. J Lab Clin Med. 1989;114:368-377[Medline] [Order article via Infotrieve]. 130. Kohgo Y, Niitsu Y, Kondo H, et al. Serum transferrin receptor as a new index of erythropoiesis. Blood. 1987;70:1955-1958[Abstract/Free Full Text]. 131. Suominen P, Punnonen K, Rajamaki A, Irjala K. Serum transferrin receptor and transferrin receptor-ferritin index identify healthy subjects with subclinical iron deficits. Blood. 1998;92:2934-2938[Abstract/Free Full Text]. 132. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD. Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med. 1992;19:385-390. 133. Suominen P, Punnonen K, Rajamaki A, Irjala K. Evaluation of new immunoenzymometric assay for measuring soluble transferrin receptor to detect iron deficiency in anemic patients. Clin Chem. 1997;43:1641-1646[Abstract/Free Full Text]. 134. Cazzola M, Ponchio L, de Benedetti F, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood. 1996;87:4824-4380[Abstract/Free Full Text]. 135. Beguin Y, Loo M, R'Zik S, et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood. 1993;82:2010-2016[Abstract/Free Full Text]. 136. Cook JD, Skikne BS, Baynes RD. Serum transferrin receptor. Annu Rev Med. 1993;44:63-74[Medline] [Order article via Infotrieve]. 137. Ahluwalia N, Skikne BS, Savin V, Chonko A. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis. 1997;30:532-541[Medline] [Order article via Infotrieve]. 138. Skikne B. Circulating transferrin receptor assaycoming of age. Clin Chem. 1998;44:7-9[Free Full Text]. 139. Erslev AJ. Erythropoietin. N Engl J Med. 1991;324:1339-1344[Medline] [Order article via Infotrieve]. 140. Krantz SB. Erythropoietin. Blood. 1991;778:419-434. 141. Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol. 1994;68:215-223[Medline] [Order article via Infotrieve]. 142. Miller CB, Jones RJ, Pianitadosi S, Abeloff MD, Spivak JL. Decreased erythropoetin response in patients with the anemia of cancer. N Engl J Med. 1990;322:1689-1692[Abstract]. 143. Spivak JL, Barnes DC, Fuchs E, Quinn TC. Serum immuno reactive erythropoietin in HIV-infected patients. JAMA. 1989;261:3104-3107[Abstract/Free Full Text]. 144. Bauer AN, Dessypris EN, Goldwasser E, Krantz SB. Blunted erythropoietin response to anemia in rheumatoid arthritis. Br J Haematol. 1987;66:559-564[Medline] [Order article via Infotrieve]. 145. Thompson JA, Gilliland DG, Prchal J, et al. Effects of recombinant human erythropoietin combined with granulocyte macrophage colony-stimulating factor in the treatment of patients with myeloplastic syndrome. Blood 2000;95:1175-1179[Abstract/Free Full Text]. 146. Ludwig H, Fritze, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoieitin treatment of anemia assocated with multiple myeloma. N Engl J Med. 1990;322:1693-1699[Abstract]. 147. Pincus T, Olson NJ, Russel IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in patients with rheumatoid arthritis. Am J Med. 1990;89:161-168[Medline] [Order article via Infotrieve]. 148. Abels R, Larholt K, Krantz K, Bryant E. Recombinant human erythropoietin for the treatment of the anemia of cancer. In: Murphy MJ Jr, ed. Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology. Dayton, OH: Alpha Med; 1990:121-141. 149. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyians S, Vadhan-Raj S. Impact of therapy with erythropoietin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218-1234[Abstract/Free Full Text]. 150. Glaspy B, Demetri G, Cremieux P. Does baseline endogenous erythropoietin level impact hemoglobin (Hb) response to rHuEPO in cancer patients [abstract]? Blood. 1999;94:15B. 151. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood. 1998;91:2139-2145[Abstract/Free Full Text]. 152. Teruel JL, Marcen R, Navarro JF, et al. Influence of body iron stores on the serum erythropoietin concentration in hemodialyzed patients. Am J Nephrol. 1994;14:95-98[Medline] [Order article via Infotrieve]. 153. Erslev AJ. The effect of hemolysates on red cell production and erythropoietin release. J Lab Clin Med. 1971;78:1-7[Medline] [Order article via Infotrieve]. 154. Birgegard G, Wide L, Simonsson B. Marked erythropoietin increase before fall in hemoglobin after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. Br J Haematol. 1989;72:462-468[Medline] [Order article via Infotrieve]. 155. Cazzola M, Ponchio L, de Benedetti F, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset, juvenile chronic arthritis. Blood. 1996;87:4824-4830. 156. Corazza F, Beguin Y, Bergmann P, et al. Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood. 1998;92:1793-1798[Abstract/Free Full Text]. 157. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992;80:1639-1647[Abstract/Free Full Text]. 158. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987-1994[Abstract/Free Full Text]. 159. Muirhead M, Bargman J, Burgess E, et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Disease. 1995;26:S1-S24[Medline] [Order article via Infotrieve]. 160. Auerbach M, Witt D, Toler W, Fierstein M, Lerner RG, Ballard H. Clinical use of the total dose intravenous of iron dextran. J Lab Clin Med. 1988;111:566-569[Medline] [Order article via Infotrieve]. 161. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980;243:1726-1729[Abstract/Free Full Text]. 162. Woodman J, Shaw RJ, Shipman AJ, Edwards AM. A surveillance program on a long-established product: Imferon (iron dextran BP). Pharmaceut Med. 1987;1:289-296. 163. Fishbane S, Ungureanu VD, Maeska JK, Kaupke CJ, Lim V, Wish S. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996;28:529-534[Medline] [Order article via Infotrieve]. 164. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis. 1998;31:81-86[Medline] [Order article via Infotrieve]. 165. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextran. Am J Kidney Dis. 1999;33:464-470[Medline] [Order article via Infotrieve]. 166. Sunder-Plassmann G, Horl WH. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Safety. 1997;17:241-250[Medline] [Order article via Infotrieve]. 167. Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A. Intravenous ferric saccharate as an iron supplementation in dialysis patients. Nephron. 1996;72:413-417[Medline] [Order article via Infotrieve]. 168. Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995;10:2070-2076[Abstract/Free Full Text]. 169. Nissenson AR, Lindsay RM, Swan S, Sellgman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American trial. Am J Kidney Dis. 1999;33:471-482[Medline] [Order article via Infotrieve]. 170. Calvar C, Mata D, Alonso C, Ramos B, Lopez de Novales E. Intravenous administration of iron gluconate during haemodialysis. Nephrol Dial Transplant. 1997;12:574-575[Free Full Text]. 171. Pascual J, Teruel JL, Liano F, Sureda A, Ortuna J. Serious adverse reactions after intravenous ferric gluconate. Nephrol Dial Transplant. 1992;7:271-272[Free Full Text]. 172. Zanen AL, Adriaansen HJ, Van Bommel EFH, Posthuma R, Th de Jong GM. "Over saturation" of transferrin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transplant. 1996;11:820-824[Abstract/Free Full Text]. 173. Seligman PA, Schleicher RB. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem. 1999;45:898-900[Free Full Text]. 174. Henderson PA, Hillman RS. Characteristics of iron dextran utilization in man. Blood. 1969;34:357-375[Abstract/Free Full Text]. 175. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med. 1997;336:933-938[Free Full Text]. 176. Messmer K. Consensus statement: using epoietin alfa to decrease the risk of allogeneic blood transfusion in the surgical setting. Semin Hematol. 1996;33:73-80. 177. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regiments of erythropoietin alfa in patients undergoing major orthopedic surgery. Am J Orthop. 1996;25:544-552[Medline] [Order article via Infotrieve]. 178. Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. J Bone Joint Surg Am. 1996;78:62-72[Abstract/Free Full Text]. 179. Doolittle RF. Biotechnologythe enormous cost of success. N Engl J Med. 1991;324:360-362. 180. Coyle D, Lee KM, Ferguson DA, Laupacis A. Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med. 1999;9:21-39[Medline] [Order article via Infotrieve]. 181. Tielemans CL, Lenclud CM, Wens R, Collart FE, Dratwa M. Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections: beneficial effects of desferrioxamine. Nephrol Dial Transplant. 1989;4:883-887[Abstract/Free Full Text]. 182. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicenter prospective survey. Nephrol Dial Transplant. 1995;10:377-381[Abstract/Free Full Text]. 183. Collins A, Ebben J, Ma J. Frequent IV iron dosing is associated with higher infectious deaths. J Am Soc Nephrol [abstract]. 1997;8:190A. 184. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86:803-811[Abstract/Free Full Text]. 185. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart disease. N Engl J Med. 1994;330:1119-1122[Abstract/Free Full Text]. 186. Milman N, Kichoff M. Relationship between serum ferritin and risk factors for ischaemic heart disease in 2235 Danes aged 30-60 years. J Intern Med. 1999;245:423-433[Medline] [Order article via Infotrieve]. 187. Matzke GR. Intravenous iron supplementation in end-stage renal disease patients. Am J Kidney Dis. 1999;33:595-597[Medline] [Order article via Infotrieve]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: I. Theurl, E. Aigner, M. Theurl, M. Nairz, M. Seifert, A. Schroll, T. Sonnweber, L. Eberwein, D. R. Witcher, A. T. Murphy, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications Blood, May 21, 2009; 113(21): 5277 - 5286. [Abstract] [Full Text] [PDF] S. B. Silverstein, J. A. Gilreath, and G. M. Rodgers Intravenous Iron Therapy: A Summary of Treatment Options and Review of Guidelines Journal of Pharmacy Practice, December 1, 2008; 21(6): 431 - 443. [Abstract] [PDF] J. Thomas and A. Martinez Blood conservation in the critically ill Am. J. Health Syst. Pharm., August 15, 2007; 64(16_Supplement_11): S11 - S18. [Abstract] [Full Text] [PDF] B. V. Alvarez, D. M. Kieller, A. L. Quon, M. Robertson, and J. R. Casey Cardiac hypertrophy in anion exchanger 1-null mutant mice with severe hemolytic anemia Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1301 - H1312. [Abstract] [Full Text] [PDF] D. H. Henry, N. V. Dahl, M. Auerbach, S. Tchekmedyian, and L. R. Laufman Intravenous Ferric Gluconate Significantly Improves Response to Epoetin Alfa Versus Oral Iron or No Iron in Anemic Patients with Cancer Receiving Chemotherapy Oncologist, February 1, 2007; 12(2): 231 - 242. [Abstract] [Full Text] [PDF] N. Haiden, J. Schwindt, F. Cardona, A. Berger, K. Klebermass, M. Wald, C. Kohlhauser-Vollmuth, B. Jilma, and A. Pollak Effects of a Combined Therapy of Erythropoietin, Iron, Folate, and Vitamin B12 on the Transfusion Requirements of Extremely Low Birth Weight Infants Pediatrics, November 1, 2006; 118(5): 2004 - 2013. [Abstract] [Full Text] [PDF] T. S. Walsh and E.-E.-D. Saleh Anaemia during critical illness Br. J. Anaesth., September 1, 2006; 97(3): 278 - 291. [Full Text] [PDF] J. A. Widness, R. E. Serfass, N. Haiden, S. E. Nelson, K. A. Lombard, and A. Pollak Erythrocyte Iron Incorporation but Not Absorption Is Increased by Intravenous Iron Administration in Erythropoietin-Treated Premature Infants J. Nutr., July 1, 2006; 136(7): 1868 - 1873. [Abstract] [Full Text] [PDF] N. Haiden, K. Klebermass, F. Cardona, J. Schwindt, A. Berger, C. Kohlhauser-Vollmuth, B. Jilma, and A. Pollak A Randomized, Controlled Trial of the Effects of Adding Vitamin B12 and Folate to Erythropoietin for the Treatment of Anemia of Prematurity Pediatrics, July 1, 2006; 118(1): 180 - 188. [Abstract] [Full Text] [PDF] I. Theurl, V. Mattle, M. Seifert, M. Mariani, C. Marth, and G. Weiss Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease Blood, May 15, 2006; 107(10): 4142 - 4148. [Abstract] [Full Text] [PDF] C. Ullrich, A. Wu, C. Armsby, S. Rieber, S. Wingerter, C. Brugnara, D. Shapiro, and H. Bernstein Screening Healthy Infants for Iron Deficiency Using Reticulocyte Hemoglobin Content JAMA, August 24, 2005; 294(8): 924 - 930. [Abstract] [Full Text] [PDF] G. Weiss and L. T. Goodnough Anemia of Chronic Disease N. Engl. J. Med., March 10, 2005; 352(10): 1011 - 1023. [Full Text] [PDF] P. Pedrazzoli, C. Tullio, G. Cerea, and S. Siena Iron Supplement in Cancer Patients Receiving Erythropoietin J. Clin. Oncol., November 1, 2004; 22(21): 4428 - 4428. [Full Text] [PDF] K. K. Ballen, P. S. Becker, B. Y. Yeap, B. Matthews, D. H. Henry, and P. A. Ford Autologous Stem-Cell Transplantation Can Be Performed Safely Without the Use of Blood-Product Support J. Clin. Oncol., October 15, 2004; 22(20): 4087 - 4094. [Abstract] [Full Text] [PDF] D. H. Henry, P. Bowers, M. T. Romano, and R. Provenzano Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine Arch Intern Med, February 9, 2004; 164(3): 262 - 276. [Abstract] [Full Text] [PDF] A. Schubert, R. J. Przybelski, J. F. Eidt, L. C. Lasky, K. E. Marks, M. Karafa, A. C. Novick, J. F. O'Hara Jr., M. E. Saunders, J. W. Blue, et al. Diaspirin-Crosslinked Hemoglobin Reduces Blood Transfusion in Noncardiac Surgery: A Multicenter, Randomized, Controlled, Double-Blinded Trial Anesth. Analg., August 1, 2003; 97(2): 323 - 332. [Abstract] [Full Text] [PDF] K. Binley, Z. Askham, S. Iqball, H. Spearman, L. Martin, M. de Alwis, A. J. Thrasher, R. R. Ali, P. H. Maxwell, S. Kingsman, et al. Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy Blood, September 18, 2002; 100(7): 2406 - 2413. [Abstract] [Full Text] [PDF] A. Lorentz, T. Frietsch, and L. T. Goodnough Transfusion Medicine N. Engl. J. Med., August 15, 2002; 347(7): 538 - 539. [Full Text] [PDF] M. S. Gordon Managing Anemia in the Cancer Patient: Old Problems, Future Solutions Oncologist, August 1, 2002; 7(4): 331 - 341. [Abstract] [Full Text] [PDF] R. K. Ohls, R. A. Ehrenkranz, L. L. Wright, J. A. Lemons, S. B. Korones, B. J. Stoll, A. R. Stark, S. Shankaran, E. F. Donovan, N. C. Close, et al. Effects of Early Erythropoietin Therapy on the Transfusion Requirements of Preterm Infants Below 1250 Grams Birth Weight: A Multicenter, Randomized, Controlled Trial Pediatrics, October 1, 2001; 108(4): 934 - 942. [Abstract] [Full Text] [PDF] J. Seppen, S. C. Barry, B. Harder, and W. R. A. Osborne Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin Blood, August 1, 2001; 98(3): 594 - 596. [Abstract] [Full Text] [PDF] D. G. Gilliland The Diverse Role of the ETS Family of Transcription Factors in Cancer: Commentary re: B. Davidson, Ets-1 Messenger RNA Expression Is a Novel Marker of Poor Survival in Ovarian Carcinoma. Clin. Cancer Res., 7: 551-557, 2001. Clin. Cancer Res., March 1, 2001; 7(3): 451 - 453. [Full Text] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Goodnough, L. T. Articles by Brugnara, C. Search for Related Content PubMed PubMed Citation Articles by Goodnough, L. T. Articles by Brugnara, C. Related Collections Hematopoiesis and Stem Cells Red Cells Review Articles Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020